Harm Reduction for Adolescents and Young Adults During the COVID-19 Pandemic: A Case Study of Community Care in Reach.
COVID-19
adolescent
harm reduction
opioid epidemic
opioid-related disorders
substance use
young adult
youth
Journal
Public health reports (Washington, D.C. : 1974)
ISSN: 1468-2877
Titre abrégé: Public Health Rep
Pays: United States
ID NLM: 9716844
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
pubmed:
7
3
2021
medline:
13
5
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic has challenged the ability of harm reduction programs to provide vital services to adolescents, young adults, and people who use drugs, thereby increasing the risk of overdose, infection, withdrawal, and other complications of drug use. To evaluate the effect of the COVID-19 pandemic on harm reduction services for adolescents and young adults in Boston, we conducted a quantitative assessment of the Community Care in Reach (CCIR) youth pilot program to determine gaps in services created by its closure during the peak of the pandemic (March 19-June 21, 2020). We also conducted semistructured interviews with staff members at 6 harm reduction programs in Boston from April 27 through May 4, 2020, to identify gaps in harm reduction services, changes in substance use practices and patterns of engagement with people who use drugs, and how harm reduction programs adapted to pandemic conditions. During the pandemic, harm reduction programs struggled to maintain staffing, supplies, infection control measures, and regular connection with their participants. During the 3-month suspension of CCIR mobile van services, CCIR missed an estimated 363 contacts, 169 units of naloxone distributed, and 402 syringes distributed. Based on our findings, we propose the following recommendations for sustaining harm reduction services during times of crisis: pursuing high-level policy changes to eliminate political barriers to care and fund harm reduction efforts; enabling and empowering harm reduction programs to innovatively and safely distribute vital resources and build community during a crisis; and providing comprehensive support to people to minimize drug-related harms.
Identifiants
pubmed: 33673755
doi: 10.1177/0033354921999396
pmc: PMC8580390
doi:
Substances chimiques
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-308Références
Int J Drug Policy. 2016 May;31:25-31
pubmed: 26919826
Int J Drug Policy. 2018 Oct;60:82-88
pubmed: 30176422
Addict Sci Clin Pract. 2018 May 7;13(1):15
pubmed: 29730987
J Adolesc Health. 2019 Nov;65(5):571-572
pubmed: 31648752
Subst Use Misuse. 2019;54(6):998-1006
pubmed: 30767590
MMWR Morb Mortal Wkly Rep. 2018 Mar 09;67(9):279-285
pubmed: 29518069
Harm Reduct J. 2019 Jan 8;16(1):3
pubmed: 30621699
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8
pubmed: 25950251
NCHS Data Brief. 2018 Nov;(329):1-8
pubmed: 30500323
J Adolesc Health. 2012 Dec;51(6):535-43
pubmed: 23174462
Front Public Health. 2020 Sep 25;8:501
pubmed: 33102413